In human ovarian cancer cells (HeyA8 cells), talazoparib also showed the strongest activity of trapping PARP-1, and could be detected at subnanomolar concentrations, while olaparib showed significant capture of PARP-1 at its concentrations as low as 10 to 100 nM, which had a moderate trapping capacity (20). This evidence concerns the gene PARP1 and ovarian carcinoma.